The landscape of retesting in childhood-onset idiopathic growth hormone deficiency and its reversibility: a systematic review and meta-analysis.

Autor:	Laurer E; 1Department of Pediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria., Sirovina A; 1Department of Pediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria., Blaschitz A; 1Department of Pediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria., Tischlinger K; 1Department of Pediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria., Montero-Lopez R; 1Department of Pediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria., Hörtenhuber T; 1Department of Pediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria., Wimleitner M; 1Department of Pediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria., Högler W; 1Department of Pediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria.
Jazyk:	angličtina
Zdroj:	European journal of endocrinology [Eur J Endocrinol] 2022 Jun 29; Vol. 187 (2), pp. 265-278. Date of Electronic Publication: 2022 Jun 29 (Print Publication: 2022).
DOI:	10.1530/EJE-21-1179
Abstrakt:	Objective: Children diagnosed with idiopathic isolated growth hormone deficiency (IGHD) are frequently observed to no longer be GH-deficient at a later stage of growth as a result of 'GHD reversal'. Reevaluation of GH status by stimulation test is currently incorporated into management guidelines at attainment of final height (FH). Over the past three decades, numerous studies have evaluated reversal rates using different methodologies including crucial parameters like GHD aetiology, GH cut-off and retesting time point, with heterogeneous results. We aimed to systematically analyse the reversibility of childhood-onset IGHD dependent on retesting GH cut-offs and retesting time points. Methods: PubMed, Cochrane Library, TRIP database and NHS Evidence were searched for publications investigating the reversibility of IGHD from database initiation to 30 June 2020 following PRISMA recommendations. Study cohorts were pooled according to retesting GH cut-off and time point. Reversal rates were calculated using random-effects models. Results: Of the 29 studies initially identified, 25 provided sufficient detail for IGHD analysis, resulting in 2030 IGHD patient data. Reversal rates decreased significantly as the retesting GH cut-off increased (P = 0.0013). Pooled (95% CI) reversal rates were 80% (59-92%, n = 227), 73% (62-81%, n = 516) and 55% (41-68%, n = 1287) for cohorts using retesting GH cut-offs of 3-4 ng/mL, 5-6 ng/mL and 7.7-10 ng/mL, respectively. Individuals retested at FH (n = 674) showed a pooled reversal rate of 74% (64-82%) compared to 48% (25-71%) when retested before FH (n = 653). Conclusion: Provided evidence supports reevaluation of current IGHD management guidelines. The high reversal rates should instigate consideration of early retesting.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu